Europe Acute Lung Injury Market Analysis, Size, and Share by 2028

The Europe acute lung injury market is expected to grow from US$ 156.55 million in 2021 to US$ 211.12 million by 2028; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028.

The UK, Germany, France, Italy, and Spain are major economies in Europe. Growing prevalence of respiratory diseases is expected to fuel the market growth. The high prevalence of respiratory conditions is associated with the decrease in the size of the upper airway lumen in the aging population. Lung disorders are among the most common medical conditions across the region. People suffer from various sorts of respiratory diseases. Smoking, infections, and genetic factors are among the common factors responsible for respiratory disorders. Medical conditions such as COPD, asthma, chronic bronchitis, cystic fibrosis, and lung cancer are significant public health burdens. In addition, the World Health Organization (WHO) states that millions of people die from lung cancer every year, making it the most common lethal infectious disease. In addition, 91% of the population lives in cities and places where the air quality is not optimum, as recommended by the WHO.  Patients suffering from these respiratory disorders commonly experience difficulty in breathing. The respiratory failure associated with acute lung injury, or the acute respiratory distress syndrome (ARDS) is one of the most critical contributors to postoperative mortality. Moreover, state, and local health departments, and other clinical and public health associates continue to monitor smoking e-cigarette or vaping product use associated lung injury (EVALI). Thus, all the above-mentioned factors are expected to result in the growth of the Europe acute lung injury market during the forecast period.

In case of COVID-19, Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of September 16, 2021, Spain, UK, Italy, Germany, and France recorded 4,922,249; 7,312,683; 4,618,040; 4,117,263; and 6,926,604, respectively, COVID-19 cases, and the deaths toll is also high in these countries. In addition, Novel coronavirus-associated disease (COVID-19) was first detected in Spain on 31 January 2020, with more than 204 178 cases subsequently identified in 3 months.1 Severe COVID-19 is associated with high circulating levels of inflammatory cytokines akin to a cytokine release syndrome that frequently results in respiratory failure. To date, scant histopathological information of infected patients is available. Few descriptions of histopathological findings have mainly reported pneumonitis and diffuse alveolar damage (DAD).2–5 To advance in the knowledge of COVID-19-associated tissue damage is important to understand the mechanisms of damage caused by SARS-COV-2.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe acute lung injury market. The Europe acute lung injury market is expected to grow at a good CAGR during the forecast period.  

Europe Acute Lung Injury Market Segmentation  
Europe Acute Lung Injury Market – By Therapy

• Mechanical Ventilation
• Fluid Management
• Pharmacotherapy
• Adjunctive Procedures

Europe Acute Lung Injury Market – By End User

• Hospitals
• Ambulatory Surgery Centers
• Others

Europe Acute Lung Injury Market, by Country

• UK
• Germany
• France 
• Italy
• Spain
• Rest of Europe

Europe Acute Lung Injury Market - Companies Mentioned

• Apeiron Biologics AG
• APEPTICO Forschung und Entwicklung GmbH
• GlaxoSmithKline Plc
• Histocell
• Stemedica Cell Technologies, Inc
• Windtree Therapeutics, Inc.

Europe Acute Lung Injury Report Scope